Formulation Development
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients With Non-CNS MET Fusion Solid Tumors From its Phase 2 Trial
Apollomics Inc. recently announced positive preliminary clinical data for the cohort of patients with non-CNS MET fusion solid tumors from the Phase 2 SPARTA trial…
Evonik Expands its Formulation Capabilities for Lipid Nanoparticles Used for mRNA & Gene Therapies
Evonik is collaborating with KNAUER Wissenschaftliche Geräte GmbH, a manufacturer of scientific instruments, to improve the upscaling of lipid nanoparticle (LNP) formulations. By combining Evonik’s…
Purdue & Akston Biosciences Sign Partnership Agreement for Dog Cancer Drug Development
Akston Biosciences Corporation and Purdue University recently announced a strategic partnership to co-develop an anti-cPD-L1 monoclonal antibody (mAb) immunotherapy to treat cancer in dogs. The underlying…
Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial
Lipella Pharmaceuticals Inc. recently announced the dosing of the first two patients with LP-310 in its Phase 2a clinical trial in Oral Lichen Planus (OLP)…
Eclipse Life Sciences Initiates Phase 2 Study for Novel Ophthalmology Steroid Implant for Diabetic Macular Edema
Eclipse Life Sciences, Inc. recently announced it has enrolled and dosed its first patient in the BETTIS-1 Phase 2 clinical trial (NCT06536491) for EC-104 fluocinolone…
MBX Biosciences Doses First Patient in Phase 2 Avail Trial for the Treatment of Hypoparathyroidism
MBX Biosciences, Inc. recently it has dosed the first patient in its Phase 2 Avail trial of MBX 2109, the company’s parathyroid hormone (PTH) peptide…
IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology With 100% of Treated AML Patients in Complete Remission& Receives FDA Guidance for Registrational Trial of INB-100
IN8bio, Inc. recently announced updated positive clinical data from both of the company’s Phase 1 investigator-sponsored trials of INB-100 for hematological malignancies and INB-200 for…
Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for the Treatment of Duchenne Muscular Dystrophy
Wave Life Sciences Ltd. recently announced the US FDA has granted Rare Pediatric Disease Designation to WVE-N531 for the treatment of boys with Duchenne muscular…
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination With Zbtb46 mRNA Delivered With SemaPhore Nanoparticles in Animal Tumor Models
Altamira Therapeutics Ltd. recently announced the publication of a peer-reviewed article in Nature Immunology highlighting the important role of the Zbtb46 gene in the control…
Abzena Supplies Clinical Trial Material for Angiex’s Phase 1 Study of First-in-Class TM4SF1-Directed ADC
Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, recently announced that patient dosing has begun for their Phase 1 clinical trial…
ANEW MEDICAL Announces Patents Issued in Major Asian Markets for Use of Genetic Therapy
ANEW MEDICAL, INC. recently announced the grant and issuance of patent number HK1259628 protecting the development of novel genetic approaches for the treatment of neurodegenerative…
Conduit Pharmaceuticals Enters Exclusive License Agreement With AstraZeneca for Multiple Assets
Conduit Pharmaceuticals Inc. recently announced it has entered into an agreement with AstraZeneca to exclusively license rights to develop AZD1656 and AZD5658, both HK-4 glucokinase…
Apellis & Sobi Announce Positive Topline Results From Phase 3 Study of Pegcetacoplan in C3G & Primary IC-MPGN
Apellis Pharmaceuticals, Inc. recently announced positive topline results from the Phase 3 VALIANT study investigating systemic pegcetacoplan in patients with C3 glomerulopathy (C3G) or primary immune…
Palisade Bio Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis
Palisade Bio, Inc. provided a progress update on the advancement of development for its lead drug candidate, PALI-2108 towards initiation of Phase 1 clinical trials in…
Oragenics Announces Concussion Drug Successfully Clears FDA-Required Cardiotoxicity Testing
Oragenics, Inc. recently announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity. ONP-002 is a new…
Nutcracker Therapeutics Announces Publication in ACS Nano Demonstrating the Therapeutic Viability of Nutshell Delivery Vehicles
Nutcracker Therapeutics, Inc. recently announced the publication of its latest peer-reviewed paper, which explores the fundamental aspects of its Nutshell platform of peptoid-based mRNA delivery vehicles.…
Agios to Receive $1.1 Billion in Milestone Payments
Agios Pharmaceuticals, Inc. recently announced it will receive a total of $1.1 billion in milestone payments following US FDA approval of vorasidenib for adult and…
Silo Pharma Announces Partnership With Global CRO for CNS Homing Peptide
Silo Pharma, Inc. recently announced it has entered into an agreement with WuXi AppTec (Hong Kong) Limited for a preclinical small animal study of SPU-16,…
Levicept Announces Positive Results of Phase 2 Trial of Novel Neurotrophin-3 Inhibitor for the Treatment of Patients With Moderate to Severe Osteoarthritis
Levicept Ltd recently announced positive results from its Phase 2 trial of LEVI-04 a novel and first in class neurotrophin-3 (NT-3) inhibitor, showing that LEVI-04…
George Medicines Files NDA for Novel Low Dose Triple Combination for Treatment of Hypertension Following Successful Phase 3 Development Program
George Medicines recently announced its submission to the US FDA of a New Drug Application (NDA) for GMRx2, George Medicines’ lead pipeline candidate for the…
